CIPLA | SUN PHARMA | CIPLA/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.4 | 54.0 | 60.1% | View Chart |
P/BV | x | 4.0 | 4.6 | 86.6% | View Chart |
Dividend Yield | % | 0.5 | 1.1 | 44.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-22 |
SUN PHARMA Mar-22 |
CIPLA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,083 | 931 | 116.4% | |
Low | Rs | 806 | 593 | 136.0% | |
Sales per share (Unadj.) | Rs | 269.7 | 161.1 | 167.4% | |
Earnings per share (Unadj.) | Rs | 31.7 | 14.2 | 223.5% | |
Cash flow per share (Unadj.) | Rs | 44.8 | 23.1 | 193.5% | |
Dividends per share (Unadj.) | Rs | 5.00 | 10.00 | 50.0% | |
Avg Dividend yield | % | 0.5 | 1.3 | 40.3% | |
Book value per share (Unadj.) | Rs | 257.8 | 200.1 | 128.8% | |
Shares outstanding (eoy) | m | 806.81 | 2,399.34 | 33.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 4.7 | 74.1% | |
Avg P/E ratio | x | 29.8 | 53.7 | 55.5% | |
P/CF ratio (eoy) | x | 21.1 | 32.9 | 64.1% | |
Price / Book Value ratio | x | 3.7 | 3.8 | 96.3% | |
Dividend payout | % | 15.8 | 70.4 | 22.4% | |
Avg Mkt Cap | Rs m | 762,177 | 1,827,693 | 41.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 35,299 | 73,008 | 48.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 217,633 | 386,545 | 56.3% | |
Other income | Rs m | 3,217 | 14,374 | 22.4% | |
Total revenues | Rs m | 220,851 | 400,919 | 55.1% | |
Gross profit | Rs m | 43,298 | 53,150 | 81.5% | |
Depreciation | Rs m | 10,520 | 21,437 | 49.1% | |
Interest | Rs m | 1,064 | 1,274 | 83.5% | |
Profit before tax | Rs m | 34,933 | 44,813 | 78.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 9,338 | 10,755 | 86.8% | |
Profit after tax | Rs m | 25,595 | 34,058 | 75.1% | |
Gross profit margin | % | 19.9 | 13.7 | 144.7% | |
Effective tax rate | % | 26.7 | 24.0 | 111.4% | |
Net profit margin | % | 11.8 | 8.8 | 133.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 147,108 | 350,150 | 42.0% | |
Current liabilities | Rs m | 49,129 | 172,006 | 28.6% | |
Net working cap to sales | % | 45.0 | 46.1 | 97.7% | |
Current ratio | x | 3.0 | 2.0 | 147.1% | |
Inventory Days | Days | 63 | 149 | 42.2% | |
Debtors Days | Days | 6 | 100 | 5.7% | |
Net fixed assets | Rs m | 119,415 | 318,882 | 37.4% | |
Share capital | Rs m | 1,614 | 2,399 | 67.3% | |
"Free" reserves | Rs m | 206,364 | 477,713 | 43.2% | |
Net worth | Rs m | 207,977 | 480,112 | 43.3% | |
Long term debt | Rs m | 4,162 | 2,299 | 181.0% | |
Total assets | Rs m | 266,523 | 669,032 | 39.8% | |
Interest coverage | x | 33.8 | 36.2 | 93.5% | |
Debt to equity ratio | x | 0 | 0 | 417.9% | |
Sales to assets ratio | x | 0.8 | 0.6 | 141.3% | |
Return on assets | % | 10.0 | 5.3 | 189.4% | |
Return on equity | % | 12.3 | 7.1 | 173.5% | |
Return on capital | % | 17.0 | 9.6 | 177.6% | |
Exports to sales | % | 26.2 | 0 | - | |
Imports to sales | % | 8.2 | 0 | - | |
Exports (fob) | Rs m | 57,094 | NA | - | |
Imports (cif) | Rs m | 17,803 | NA | - | |
Fx inflow | Rs m | 60,180 | 106,331 | 56.6% | |
Fx outflow | Rs m | 17,803 | 71,874 | 24.8% | |
Net fx | Rs m | 42,376 | 34,456 | 123.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33,259 | 89,845 | 37.0% | |
From Investments | Rs m | -18,719 | -57,247 | 32.7% | |
From Financial Activity | Rs m | -15,998 | -51,935 | 30.8% | |
Net Cashflow | Rs m | -1,323 | -17,648 | 7.5% |
Indian Promoters | % | 13.5 | 54.5 | 24.8% | |
Foreign collaborators | % | 20.1 | 0.0 | - | |
Indian inst/Mut Fund | % | 49.0 | 34.6 | 141.5% | |
FIIs | % | 27.6 | 15.0 | 184.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 66.4 | 45.5 | 145.8% | |
Shareholders | 418,910 | 647,167 | 64.7% | ||
Pledged promoter(s) holding | % | 0.0 | 4.0 | - |
Compare CIPLA With: DR. REDDYS LAB LUPIN PIRAMAL ENTERPRISES AUROBINDO PHARMA ZYDUS LIFESCIENCES
After opening the day on a flat note, Indian share markets extended gains as the session progressed and ended near day's high.